Bladder Cancer Articles

European Urology Oncology – Bladder Cancer Articles

These eight (8) European Urology Oncology (EUO) bladder cancer articles have Open Access status.

Can biomarkers guide the use of neoadjuvant chemotherapy in T2 bladder cancer?

H. Barton Grossman, MDa; Joaquim Bellmunt, MD, PhDb; Peter C. Black, MDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30077-X/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.06.002

Recurrent Ta Low-Grade Non-Muscle-Invasive Bladder Cancer (NIMBC): What are the Options?

Morgan Rouprêt, MD, PhDa; Per-Uno Malmstrom, MD, PhDb; Peter Black, MDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30078-1/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.06.003

Management of Patients with Normal Cystoscopy and Negative Urine Biomarkers/Positive Cytology, or Negative Cytology/Positive Urine Biomarkers

Joan Palou, MDa; Maurizio Brausi, MDb; James W.F. Catto, PhDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30098-7/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.06.017

How to Treat Multifocal Ta High-grade Disease if BCG is Unavailable

J.A. Witjes, MDa; Maurizio Brausi, MDb; Per-Uno Malmstrom, MDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30092-6/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.06.011

Does Variant Histology Change Management of Non-invasive Bladder Cancer (NMIBC)?

Maximilian Burger, MDa; Ashish Kamat, MDb; David McConkey, PhDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30093-8/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.06.012

How Should I Manage a Patient with Tumor Recurrence Despite Adequate BCG?

Ashish M. Kamat, MDa; Paolo Gontero, MDb; Joan Palou, MDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30094-X/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.06.013

How to Treat a Patient with T1 High-grade Disease and no Tumour on re-TURB?

Shahrokh Shariat, MDa; Paolo Gontero, MDb; James W.F. Catto, PhDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30109-9/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.07.006

Does it matter whether a T1 high-grade tumor is molecularly classified?

Arnulf Stenzl, MDa; David McConkey, PhDb; Joaquim Bellmunt, MD, PhDc
Published: https://euoncology.europeanurology.com/article/S2588-9311(19)30112-9/fulltext
DOI: https://doi.org/10.1016/j.euo.2019.07.009